Contact

Our portfolio

AMI Pharma

AMI Pharma develops therapeutics compounds for Type 1 Diabetes and autoimmune diseases. Their research, based on IP from Amsterdam UMC and Wageningen University & Research, aims to bring new treatments to the clinical trials. AMI Pharma leverages extensive pre-clinical and clinical data to advance their therapeutic pipeline.

  • Institute: Amsterdam UMC
Industry: Diabetes, Metabolic Disorders, Therapeutics
  • Founding year: 2022
Visit website

Want to get in contact about AMI Pharma?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

TrianecT
Innovating stroke diagnosis with an AI-powered portable EEG for use inside the ambulance.
Inreda Diabetic
Improving diabetes management with the AP, a closed-loop bi-hormonal artificial pancreas.
SusPhos
Upcycling phosphate waste into sustainable industrial products.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
TrianecT
Innovating stroke diagnosis with an AI-powered portable EEG for use inside the ambulance.
Inreda Diabetic
Improving diabetes management with the AP, a closed-loop bi-hormonal artificial pancreas.
SusPhos
Upcycling phosphate waste into sustainable industrial products.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
Explore full AAV portfolio
Contact